Compare stocks
Market: US
CRLCharles River Laboratories
Add stock
Ticker or company
Summary

CRL
Charles River Laboratories
$335,52Down −0,72%
Year: Up +100%
50/100★★★★★★★★Ratio would watch
Open stock pageTraffic light — 10 checks
| Check | CRL4 ✓ 1 — 4 ✕ |
|---|---|
| P/E vs its history | 403,0 |
| P/E vs industry | 403,0 |
| Forward P/E | 29,5 |
| Revenue growth, YoY | −1,2% |
| EPS growth, YoY | — |
| Net margin | 1,1% |
| Net debt / EBITDA | −0,5 |
| Free cash flow | $400 m |
| Share count over a year | −1,7% |
| Cash runway | n/anot needed |
Metrics
Best WorstNo mark — in between
| Metric · better | CRLTTM | Industry medianTTM |
|---|---|---|
| P/E TTM ↓ | 403,0 | 37,9 |
| Forward P/E ↓ | 29,5 | 29,5 |
| PEG ↓ | n/a | 3,7 |
| P/S TTM ↓ | 4,1 | 6,6 |
| EV/EBITDA ↓ | 82,1 | 29,9 |
| P/FCF ↓ | 39,1 | 38,7 |
Price, %
- CRLn/a
Returns
Best WorstNo mark — in between
| Period | CRL |
|---|---|
| 1 year | n/a |
| 3 years | n/a |
| 5 years | n/a |
| All time | n/a |
“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.
Analysts and insiders
Best WorstNo mark — in between
| CRL | |
|---|---|
| Share of “buy” | 77% |
| Beat the forecast | 4 of 4 |
| Average “surprise” | +4,5% |
| Insiders over 12 months | sales $52,1 m |
Details are on each stock page.